Solventum

solventum.com JSON

Says it is part of Thermo Fisher ScientificLegal entity KCI Medical Puerto Rico, Inc.

Sources & updates

How this name was decided

the site's published name — stated on solventum.com, x.com

Legal entity: the entity the site's own defined terms bind to itself

Profile sources

Last observed: Oct 26, 2026, 12:20 AM UTCCurrent
Record last changed: Oct 26, 2026, 12:20 AM UTC
Observations: 4,687
Sources read: 26 of 27

This collection is not finished: 1 source (declared_live) could not be read.

Legal Entities & Relationships

Thermo Fisher ScientificSays it is part of

the site says it is part of it — “Solventum’s Purification and Filtration Business is now a part of Thermo Fisher Scientific.” — solventum.com

What other sites’ records say

caseys.com links the same zendesk account

A shared account is a relationship between the sites, not by itself a common owner.

Record

Relationship evidence

Identity revision 1, last changed 2026-10-26

a declared affiliated site is a relationship the publisher states, not common ownership
a declared provider account (gift cards, hiring, ordering) is a service relationship, not an affiliation
a register party at the business's premises is a candidate operator until the Place and legal resolvers bind it
a licensed operator of the business's premises operates those locations; it is not thereby the brand's owner
an employer a job board names on the openings posts them; it is not thereby the owner or the operator
an app's store seller or developer publishes the app; neither is thereby the restaurant's owner
a menu that names a producer names it; it is not a supply contract, a volume or an exclusivity
a mail or DMARC service domain in DNS is a technical service relationship, not an affiliation
a group the site says it is part of is a public affiliation; the equity chain and buying rights are separate questions
an organization that posts the openings, sells the app or holds a program account shares services with the business; that is not affiliation or ownership
a supplier or charitable partner the site's own page names and links is the publisher's statement; it is not a contract, a volume, an exclusivity or a gift amount

Published nameSolventum
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → declared Organization name
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
Copyright line© Solventum 2026
Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://solventum.com/locations
First observed
Oct 26, 2026, 12:16 AM UTC
Read from
https://solventum.com
Self-designated entityKCI Medical Puerto Rico, Inc.
Directly observed · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/our-company/hipaa-privacy/
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
SolventumSolventum · url: https://www.solventum.com/ · logo: https://s7d9.scene7.com/is/content/mmmspinco/solventum-logo-horz-black-4 · legalName: Solventum Corporation · foundingDate: 2024-04-01
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
Solventum
Solventum
https://www.solventum.com/en-us/home/
Published by the company · confirmed Oct 26, 2026, 12:14 AM UTC
Observed via
https://www.solventum.com/en-us/home/our-company/contact-us/
First observed
Oct 26, 2026, 12:14 AM UTC
Read from
https://www.solventum.com
Solventum CorporationSolventum Corporation · url: https://investors.solventum.com · logo: https://investors.solventum.com/_assets/_5a002f87e9012c6954e2da5481718d1e/solventum/logo.png · legalName: Solventum Corporation
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/news-events/press-releases
First observed
Oct 26, 2026, 12:16 AM UTC
Read from
https://investors.solventum.com
Logo
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → declared Organization logo → declared asset on another registrable domain (scene7.com) — not the subject's own host
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
Certificate organisationSolventum Corporation
Directly observed · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
TLS certificate subject → issued by Sectigo Limited
Certificate countryUS
Directly observed · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
TLS certificate subject → issued by Sectigo Limited
Certificate state/provinceMinnesota
Directly observed · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
TLS certificate subject → issued by Sectigo Limited
Legal entity
SOLVENTUM CORPORATION · C/O CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, WILMINGTON, US-DE, 19808, US · since 2023-01-24
lei
254900I70403OSGY4M28
registrationAuthorityFileNumber
7253837
registrationAuthority
RA000602
entityStatus
ACTIVE
registrationStatus
ISSUED
jurisdiction
US-DE
legalForm
XTIQ
entityCategory
GENERAL
headquartersAddress
3M Center Building 275, 2510 Conway Ave E, Maplewood, US-MN, 55119, US
leiInitialRegistration
2023-09-25
leiLastUpdate
2026-09-24
leiNextRenewal
2027-09-25
managingLOU
5493001KJTIIGC8Y1R12
Published by a third-party source · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://api.gleif.org/api/v1/lei-records/254900I70403OSGY4M28 → printed as Solventum Corp on https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm → printed as Solventum Corp on https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → confirmed by the only GLEIF record under this legal name
First observed
Oct 26, 2026, 12:19 AM UTC
Read from
https://api.gleif.org
Interpreted by rule
gleif-lei-v2

SEC EDGAR

RegistrantSolventum Corp
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
CIK1964738
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
EIN92-2008841
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
SIC3841 Surgical & Medical Instruments & Apparatus
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Entity typeoperating
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Filer categoryLarge accelerated filer
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
State of incorporationDE
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Fiscal year end12-31
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Listed asNYSE:SOLV
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Business address1750 YANKEE DOODLE ROAD, EAGAN, MN, 55121
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Former name3M Health Care Co
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/submissions/CIK0001964738.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov

Consolidated Statements of Income

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Total net sales	8,325,000,000	8,254,000,000	8,197,000,000
Gross profit	4,451,000,000	4,593,000,000	4,693,000,000
Selling, general and administrative expenses	3,080,000,000	2,782,000,000	2,299,000,000
Research and development expenses	739,000,000	775,000,000	758,000,000
Gain on sale of business	(1,549,000,000)	0	(56,000,000)
Operating income	2,181,000,000	1,036,000,000	1,692,000,000
Interest expense, net	347,000,000	367,000,000	0
Loss on debt extinguishment, net	82,000,000	0	0
Other expense (income), net	39,000,000	64,000,000	25,000,000
Income before income taxes	1,713,000,000	605,000,000	1,667,000,000
Provision for income taxes	157,000,000	127,000,000	321,000,000
Net income	1,556,000,000	479,000,000	1,346,000,000

Show the remaining 12 line items

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Earnings per share:
Basic earnings per share (in dollars per share)	8.94	2.77	7.79
Diluted earnings per share (in dollars per share)	8.88	2.76	7.79
Weighted-average number of shares outstanding:
Basic (in shares)	174,100,000	173,200,000	172,700,000
Diluted (in shares)	175,300,000	173,700,000	172,700,000
Cost of productCost of product
Cost of productTotal net sales	6,349,000,000	6,348,000,000	6,296,000,000
Cost of productCost of sales	3,402,000,000	3,172,000,000	3,023,000,000
Cost of software and rentalsCost of software and rentals
Cost of software and rentalsTotal net sales	1,976,000,000	1,906,000,000	1,901,000,000
Cost of software and rentalsCost of sales	472,000,000	489,000,000	481,000,000

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R3.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Consolidated Statements of Comprehensive Income

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Statement of Comprehensive Income [Abstract]
Net income	1,556,000,000	479,000,000	1,346,000,000
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	420,000,000	(203,000,000)	157,000,000
Defined benefit pension and postretirement plans	38,000,000	(5,000,000)	(33,000,000)
Cash flow hedging instruments	(28,000,000)	20,000,000	0
Total other comprehensive income (loss), net of tax	430,000,000	(188,000,000)	124,000,000
Comprehensive income	1,986,000,000	291,000,000	1,470,000,000

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R4.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Consolidated Balance Sheets

	2025-12-31Dec. 31, 2025	2024-12-31Dec. 31, 2024
Current assets
Cash and cash equivalents	878,000,000	762,000,000
Accounts receivable — net of allowances of $87 and $86	1,034,000,000	1,044,000,000
Due from related parties	150,000,000	185,000,000
Inventories
Finished goods	636,000,000	539,000,000
Work in process	201,000,000	190,000,000
Raw materials and supplies	229,000,000	236,000,000
Total inventories	1,066,000,000	965,000,000
Other current assets	731,000,000	293,000,000
Total current assets	3,859,000,000	3,249,000,000
Property, plant and equipment — net	1,326,000,000	1,622,000,000

Show the remaining 24 line items

	2025-12-31Dec. 31, 2025	2024-12-31Dec. 31, 2024
Goodwill	5,704,000,000	6,377,000,000
Intangible assets — net	2,592,000,000	2,544,000,000
Other assets	814,000,000	665,000,000
Total assets	14,294,000,000	14,457,000,000
Current liabilities
Short-term borrowings and current portion of long-term debt	0	200,000,000
Accounts payable	687,000,000	618,000,000
Due to related parties	435,000,000	272,000,000
Unearned revenue	621,000,000	572,000,000
Other current liabilities	1,393,000,000	1,041,000,000
Total current liabilities	3,136,000,000	2,703,000,000
Long-term debt	5,035,000,000	7,810,000,000
Pension and postretirement benefits	363,000,000	350,000,000
Deferred income taxes	164,000,000	225,000,000
Other liabilities	547,000,000	410,000,000
Total liabilities	9,245,000,000	11,498,000,000
Commitments and contingencies (Note 12)
Equity
Common stock, par value $0.01 per share, 750,000,000 shares authorized	2,000,000	2,000,000
Additional paid-in-capital	3,876,000,000	3,771,000,000
Retained earnings	1,797,000,000	242,000,000
Accumulated other comprehensive income (loss)	(625,000,000)	(1,056,000,000)
Total equity	5,049,000,000	2,959,000,000
Total liabilities and equity	14,294,000,000	14,457,000,000

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R5.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Consolidated Balance Sheets (Parenthetical)

	2025-12-31Dec. 31, 2025	2024-12-31Dec. 31, 2024
Statement of Financial Position [Abstract]
Allowance for credit loss	87,000,000	86,000,000
Common stock par value (in dollars per share)	0.01	0.01
Common stock authorized (in shares)	750,000,000	750,000,000
Common stock issued (in shares)	173,490,864	172,785,606
Common stock outstanding (in shares)	173,490,864	172,785,606

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R6.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Consolidated Statements of Cash Flows

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Cash Flows from Operating Activities
Net income	1,556,000,000	479,000,000	1,346,000,000
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	489,000,000	555,000,000	561,000,000
Pension and postretirement benefit expense	62,000,000	34,000,000	41,000,000
Stock-based compensation expense	161,000,000	112,000,000	39,000,000
Gain on sale of business	(1,549,000,000)	0	(56,000,000)
Transaction costs(this filer’s own measure)	(111,000,000)	0	0
Deferred income taxes	(120,000,000)	(155,000,000)	(142,000,000)
Changes in assets and liabilities
Accounts receivable	34,000,000	43,000,000	(129,000,000)
Due from related parties	44,000,000	233,000,000	0

Show the remaining 25 line items

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Inventories	(139,000,000)	(132,000,000)	23,000,000
Accounts payable	104,000,000	266,000,000	105,000,000
Due to related parties	(11,000,000)	(395,000,000)	0
Accrued compensation	43,000,000	78,000,000	142,000,000
All other operating activities - net	(194,000,000)	67,000,000	(15,000,000)
Net cash provided by operating activities	369,000,000	1,185,000,000	1,915,000,000
Cash Flows from Investing Activities
Purchases of property, plant and equipment	(379,000,000)	(380,000,000)	(290,000,000)
Acquisitions, net of cash acquired	(696,000,000)	0	0
Proceeds from sale of business	3,890,000,000	0	60,000,000
Other — net	(18,000,000)	0	0
Net cash provided by (used in) investing activities	2,797,000,000	(380,000,000)	(230,000,000)
Cash Flows from Financing Activities
Repayment of debt	(3,070,000,000)	(300,000,000)	0
Net transfers to 3M(this filer’s own measure)	(33,000,000)	(8,251,000,000)	(1,553,000,000)
Proceeds from long-term debt, net of issuance costs	0	8,303,000,000	0
Other — net	46,000,000	8,000,000	1,000,000
Net cash used in financing activities	(3,057,000,000)	(240,000,000)	(1,552,000,000)
Effect of exchange rate changes on cash and cash equivalents	7,000,000	3,000,000	0
Net increase (decrease) in cash and cash equivalents	116,000,000	568,000,000	133,000,000
Cash and cash equivalents at beginning of year	762,000,000	194,000,000	61,000,000
Cash and cash equivalents at end of year	878,000,000	762,000,000	194,000,000
Supplemental Cash Flow Information
Income taxes	181,000,000	244,000,000	0
Interest	442,000,000	287,000,000	0

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R8.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Revenue by type
12 Months Ended 2025-12-31 2024-12-31 2023-12-31
Cost of product 6,349,000,000 6,348,000,000 6,296,000,000
Cost of software and rentals 1,976,000,000 1,906,000,000 1,901,000,000
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/R3.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://www.sec.gov
Long-term DebtUSD 5,035,000,000 · as at 2025-12-31 · 10-K filed 2026-02-27
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/api/xbrl/companyconcept/CIK0001964738/us-gaap/LongTermDebt.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Entity Public FloatUSD 13,100,000,000 · as at 2025-06-30 · 10-K filed 2026-02-27
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/api/xbrl/companyconcept/CIK0001964738/dei/EntityPublicFloat.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Entity Common Stock, Shares Outstandingshares 173,493,005 · as at 2026-02-18 · 10-K filed 2026-02-27
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/api/xbrl/companyconcept/CIK0001964738/dei/EntityCommonStockSharesOutstanding.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Operating Lease, CostUSD 122,000,000 · year to 2025-12-31 · 10-K filed 2026-02-27
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://data.sec.gov/api/xbrl/companyconcept/CIK0001964738/us-gaap/OperatingLeaseCost.json → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://data.sec.gov
Subsidiaries named in the annual report
- Legal Entity · State or Country of Incorporation
- KCI Medical Australia Pty Ltd · Australia
- Solventum Operations Pty. Ltd. · Australia
- KCI Austria GmbH · Austria
- KCI Medical Belgium BVBA · Belgium
- KCI Polymedics BVBA · Belgium
- Solvers Insurance Group Limited · Bermuda
- KCI Brasil Importadora E Distribuidora De Produtos Para Saude Ltda. · Brazil
- Solventum do Brasil Ltda. · Brazil
- 3M Healthcare Canada Company Limited · Canada
- Crawford Healthcare Canada Limited · Canada
- KCI Medical Canada Inc./ Fournitures Medicales KCI du Canada Inc. · Canada
Show the remaining 102
KCI APAC Holding Ltd · Cayman Islands
KCI Cayman Holdings · Cayman Islands
KCI Cayman Holdings II · Cayman Islands
KCI Medical Holdings Unlimited · Cayman Islands
KCI MS Unlimited · Cayman Islands
KCI Wound Holdings · Cayman Islands
Solventum Chile SpA · Chile
3M Healthcare (Shanghai) Co. Ltd. · China
3M Medical Devices and Materials Manufacturing (Shanghai) Co., Ltd. · China
KCI Medical (China) Co., Ltd. · China
Solventum Investments (Shanghai) Co., Ltd. · China
Solventum Material Technology (Guangzhou) Co., Ltd. · China
KCI Colombia SAS · Colombia
Solventum GBS Sociedad de Responsabilidad Limitada · Costa Rica
KCI Medical Aps · Denmark
Solventum Finland Oy · Finland
Solventum France SAS · France
Solventum Germany GmbH · Germany
Solventum Operational Real Estate GmbH & Co. KG · Germany
Solventum Real Estate GmbH · Germany
Solventum Real Estate GP GmbH · Germany
KCI Hong Kong Holding Limited · Hong Kong
KCI Medical India Private limited · India
Trimodal Softech Solutions Private Limited · India
3M Healthcare EMEA Export Limited · Ireland
KCI Manufacturing Unlimited Company · Ireland
KCI Medical Limited · Ireland
Solventum Digital Science Community Limited · Ireland
Solventum International Holdings Limited · Ireland
Solventum Ireland Limited · Ireland
Solventum Technologies Israel Ltd. · Israel
Solventum Italy S.R.L. · Italy
KCI KK · Japan
Solventum Japan GK · Japan
Solventum Japan Holdings G.K. · Japan
Solventum Japan Innovation Limited · Japan
Solventum Japan Products Limited · Japan
Solventum Korea Co., Ltd. · Korea
Solventum Malaysia Sdn. Bhd. · Malaysia
Medical Holdings Limited · Malta
Solventum México Manufacturing, S. de R.L. de C.V. · Mexico
Solventum Mexico S. de R.L. de C.V. · Mexico
Solventum Purification, S. de R.L. de C.V. · Mexico
KCI Europe Holding B.V. · Netherlands
KCI Medical B.V. · Netherlands
Solventum Holdings B.V. · Netherlands
Systagenix Wound Management B.V. · Netherlands
Systagenix Wound Management Mezz B.V. · Netherlands
KCI New Zealand Unlimited · New Zealand
KCI Medical AS · Norway
Solventum GBS Poland sp. z o.o · Poland
Solventum Poland Manufacturing Sp. z o.o · Poland
Solventum Poland sp. z o.o · Poland
SLVTM Portugal, Unipessoal Lda. · Portugal
KCI Medical Puerto Rico, Inc. · Puerto Rico
Solventum Arabia Medical Regional Headquarter Company One Person · Saudi Arabia
Solventum Arabia Trading Company (One Person) · Saudi Arabia
KCI Medical Asia Pte. Ltd. · Singapore
Systagenix Wound Management (South Africa) (Proprietary) Limited · South Africa
KCI Clinic Spain, S.L.U. · Spain
KCI Medical AB · Sweden
KCI Medical GmbH · Switzerland
Solventum Taiwan Co. Ltd · Taiwan
Solventum (Thailand) Limited · Thailand
Solventum Turkey Sağlık Ürünleri ve Tıbbi Cihaz İthalat ve Ticaret Limited Şirketi · Turkey
KCI Medical Middle East & Africa FZ-LLC · United Arab Emirates
KCI Medical Middle East & Africa Trading L.L.C · United Arab Emirates
Crawford Healthcare Holdings Limited · United Kingdom
Crawford Healthcare Limited · United Kingdom
Derms Development Limited · United Kingdom
KCI Medical Limited · United Kingdom
KCI UK Holdings Limited · United Kingdom
MModal Limited · United Kingdom
Solventum UK Holding Company Ltd · United Kingdom
Systagenix Wound Management, Limited · United Kingdom
3M Healthcare LATAM/APAC Export Corporation · United States
Acelity LLC · United States
Acera Surgical, Inc. · United States
Chiron Holdings, Inc. · United States
KCI Brazil Holdings LLC · United States
KCI Holding Company, Inc. · United States
KCI Imports, Inc. · United States
KCI International, Inc. · United States
KCI Licensing, Inc. · United States
KCI Properties Limited · United States
KCI Real Holdings, L.L.C. · United States
KCI Real Property Limited · United States
KCI USA, Inc. · United States
Kinetic Concepts, Inc. · United States
MedQuist of Delaware, Inc. · United States
MModal LLC · United States
MModal MQ Inc. · United States
MModal Services, Ltd. · United States
Multimodal Technologies, LLC · United States
Solventum Corporation · United States
Solventum Health Information Systems, Inc. · United States
Solventum Intellectual Properties Company · United States
Solventum Management LLC · United States
Solventum Orthodontics Corporation · United States
Solventum US LLC · United States
Solventum Ventures, Inc. · United States
Solventum Vietnam LLC · Vietnam
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/a202510-kexhibit21.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://www.sec.gov

COX CARRIE SMITH

director

SEC insider of Solventum Corp

Holds: 4,848 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1110753

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 4,848 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	4,848	acquired
2026-04-30	exercise or conversion of a derivative	4,916	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 4,916 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	4,916	disposed
2026-03-27	exercise or conversion of a derivative	6,336	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 6,336 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	6,336	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000111075326000006/wk-form4_1779140353.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

MAY KAREN J

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1161660

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000116166026000007/wk-form4_1779140224.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

WEILAND JOHN H

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1204663

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock Upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000120466326000007/wk-form4_1779140175.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

EISENBERG GLENN A

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1222831

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000122283126000012/wk-form4_1779140283.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Harris Bernard A Jr

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1337906

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000133790626000006/wk-form4_1779140251.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Wendell Amy McBride

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1400568

Show 6 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed
2026-03-10	open-market or private purchase	1,475 @ 68.03	acquired

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000140056826000011/wk-form4_1779140149.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

ALBAN CARLOS

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1474632

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000147463226000008/wk-form4_1779140395.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Hanson Bryan C

Chief Executive Officer · officer · director

SEC insider of Solventum Corp

Holds: 185,515 Common Stock
Holds: 0 Restricted Stock Units (a claim on shares, not shares)
Pay, year to 2025-12-31: 20,139,981 reported total · 40,020,576 actually paid
Pay, year to 2024-12-31: 39,959,767 reported total · 40,244,984 actually paid
SEC CIK: 1524349

Show 10 reported transactions

2026-09-01	shares withheld for exercise price or tax	26,468 @ 90.95	disposed
2026-09-01	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	67,261	acquired
2026-09-01	exercise or conversion of a derivativeRestricted Stock Units → 67,261 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	67,261	disposed
2026-05-13	shares withheld for exercise price or tax	13,503 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	34,315	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 34,315 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	34,315	disposed
2026-03-06	shares withheld for exercise price or tax	10,395 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	31,907	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 31,907 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	31,907	disposed
2026-03-05	grant or awardRestricted Stock Units → 105,963 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	105,963	acquired

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000152434926000008/wk-form4_1788466256.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

DeVore Susan D.

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1587697

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000158769726000008/wk-form4_1779140330.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Zieselman Neil Craig

SVP, Controller & CAO · officer

SEC insider of Solventum Corp

Holds: 6,911 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1611275

Show 1 reported transaction

2026-08-17

grant or awardRestricted Stock Units → 6,911 Common Stock · expires 2036-08-17Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of August 17, 2027; August 17, 2028; and August 17, 2029, subject to continued service through the vesting date.

6,911

acquired

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000161127526000006/wk-form4_1787083863.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Wilson Darryl L.

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1755508

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000175550826000008/wk-form4_1779140123.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

McMillan Wayde D.

Chief Financial Officer · officer

SEC insider of Solventum Corp

Holds: 48,637 Common Stock
Holds: 9,504 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1768648

Show 10 reported transactions

2026-05-13	shares withheld for exercise price or tax	4,404 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	9,503	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 9,503 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	9,503	disposed
2026-03-06	shares withheld for exercise price or tax	2,786 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	8,802	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 8,802 Common StockEach Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	8,802	disposed
2026-03-05	grant or awardRestricted Stock Units → 35,321 Common StockEach Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	35,321	acquired
2025-12-01	shares withheld for exercise price or tax	12,980 @ 85.56	disposed
2025-12-01	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	28,010	acquired
2025-12-01	exercise or conversion of a derivativeRestricted Stock Units → 28,010 Common Stock · expires 2025-12-01Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	28,010	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000176864826000005/wk-form4_1778875863.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Mily Elizabeth

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1808438

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000180843826000007/wk-form4_1779140200.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Kirberger Marcela A.

Chief Legal Affairs Officer · officer

SEC insider of Solventum Corp

Holds: 13,540 Common Stock
Holds: 4,488 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1868881

Show 10 reported transactions

2026-05-13	shares withheld for exercise price or tax	1,952 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	4,488	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 4,488 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	4,488	disposed
2026-03-06	shares withheld for exercise price or tax	1,232 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	4,180	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 4,180 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	4,180	disposed
2026-03-05	grant or awardRestricted Stock Units → 14,835 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	14,835	acquired
2025-12-01	shares withheld for exercise price or tax	1,510 @ 85.56	disposed
2025-12-01	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	3,811	acquired
2025-12-01	exercise or conversion of a derivativeRestricted Stock Units → 3,811 Common Stock · expires 2025-12-01Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,811	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000186888126000005/wk-form4_1778875745.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Gomez Tammy L

Chief Human Resources Officer · officer

SEC insider of Solventum Corp

Holds: 13,362 Common Stock
Holds: 3,960 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1937481

Show 10 reported transactions

2026-05-13	shares withheld for exercise price or tax	1,668 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	3,960	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 3,960 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	3,960	disposed
2026-03-06	shares withheld for exercise price or tax	895 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	3,300	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	3,300	disposed
2026-03-05	grant or awardRestricted Stock Units → 12,716 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	12,716	acquired
2026-01-02	shares withheld for exercise price or tax	1,332 @ 79.2	disposed
2026-01-02	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	4,342	acquired
2026-01-02	exercise or conversion of a derivativeRestricted Stock Units → 4,342 Common Stock · expires 2034-01-02Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	4,342	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000193748126000007/wk-form4_1778875889.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Edwards Shirley Ann

director

SEC insider of Solventum Corp

Holds: 3,300 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1958161

Show 5 reported transactions

2026-05-15	grant or awardRestricted Stock Units → 3,300 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest on May 15, 2027, subject to continued service through the vesting date.	3,300	acquired
2026-04-30	exercise or conversion of a derivative	3,403	acquired
2026-04-30	exercise or conversion of a derivativeRestricted Stock Units → 3,403 Common Stock · expires 2035-04-30Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	3,403	disposed
2026-03-27	exercise or conversion of a derivative	1,980	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 1,980 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	1,980	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000195816126000009/wk-form4_1779140304.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Knight Heather

Chief Commercial Officer · officer

SEC insider of Solventum Corp

Holds: 31,789 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 1967528

Show 2 reported transactions

2026-03-05	grant or awardRestricted Stock Units → 31,789 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	31,789	acquired
2025-11-17	grant or awardRestricted Stock Units → 78,751 Common Stock · expires 2035-11-17Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of November 17, 2026; November 17, 2027; and November 17, 2028, subject to continued service through the vesting date.	78,751	acquired

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196752826000002/wk-form4_1773100066.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Landucci Amy

Chief Information Officer · officer

SEC insider of Solventum Corp

Holds: 39,888 Common Stock
Holds: 4,422 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 2015813

Show 10 reported transactions

2026-05-13	shares withheld for exercise price or tax	2,017 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	4,422	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 4,422 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	4,422	disposed
2026-03-06	shares withheld for exercise price or tax	1,731 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	3,795	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 3,795 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	3,795	disposed
2026-03-05	grant or awardRestricted Stock Units → 12,716 Common StockEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	12,716	acquired
2026-02-01	shares withheld for exercise price or tax	10,453 @ 76.97	disposed
2026-02-01	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	26,921	acquired
2026-02-01	exercise or conversion of a derivativeRestricted Stock Units → 26,921 Common Stock · expires 2026-02-01Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	26,921	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000201581326000007/wk-form4_1778875666.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Harrington Paul S

Chief Supply Chain Officer · officer

SEC insider of Solventum Corp

Holds: 20,452 Common Stock
Holds: 3,960 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 2015932

Show 10 reported transactions

2026-05-13	shares withheld for exercise price or tax	1,678 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	3,960	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 3,960 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	3,960	disposed
2026-03-06	shares withheld for exercise price or tax	1,073 @ 69.41	disposed
2026-03-06	exercise or conversion of a derivative	3,300	acquired
2026-03-06	exercise or conversion of a derivativeRestricted Stock Units → 3,300 Common StockEach Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	3,300	disposed
2026-03-05	grant or awardRestricted Stock Units → 10,950 Common StockEach Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of the first, second and third anniversaries of the grant date, subject to continued service through the vesting date.	10,950	acquired
2025-12-01	shares withheld for exercise price or tax	4,528 @ 85.56	disposed
2025-12-01	exercise or conversion of a derivativeEach Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.	10,463	acquired
2025-12-01	exercise or conversion of a derivativeRestricted Stock Units → 10,463 Common Stock · expires 2025-12-01Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs are fully vested.	10,463	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000201593226000005/wk-form4_1778875833.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Wilcox Mary T

Chief Accounting Officer · officer

SEC insider of Solventum Corp

Holds: 6,904 Common Stock
Holds: 2,377 Restricted Stock Units (a claim on shares, not shares)
SEC CIK: 2016061

Show 6 reported transactions

2026-05-13	shares withheld for exercise price or tax	728 @ 74.41	disposed
2026-05-13	exercise or conversion of a derivative	2,376	acquired
2026-05-13	exercise or conversion of a derivativeRestricted Stock Units → 2,376 Common Stock · expires 2034-05-13Each Restricted Stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.The RSUs shall fully vest in three tranches, with one-third vesting on each of May 13, 2025; May 13, 2026; and May 13, 2027, subject to continued service through the vesting date.	2,376	disposed
2026-03-27	shares withheld for exercise price or tax	1,591 @ 62.76	disposed
2026-03-27	exercise or conversion of a derivative	5,199	acquired
2026-03-27	exercise or conversion of a derivativeRestricted Stock Units → 5,199 Common Stock · expires 2034-08-12Each Restricted Stock Unit ("RSU") represents a contingent right to receive 1 share of the issuer's Class A Common Stock upon settlement.The RSUs are fully vested.	5,199	disposed

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000201606126000005/wk-form4_1778875789.xml → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Other named executive officers, average
average of the named executive officers other than the chief executive
Pay, year to 2025-12-31
5,074,897 reported total · 6,948,350 actually paid
Pay, year to 2024-12-31
8,528,291 reported total · 8,801,783 actually paid
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000017/R2.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://www.sec.gov

Shareholder return and performance

	2025-12-31	2024-12-31
Value of $100 invested in this company	114.67	95.60
Value of $100 invested in the peer group	108.95	95.07
Net income	1,556,000,000	479,000,000
Constant Currency Revenue, the measure this company selected	8,384,000,000	8,296,000,000

About Solventum Corp, the SEC registrant the site links

Published by a third-party source

Observed via: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000017/R2.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About: Solventum Corp, the SEC registrant the site links
Read from: https://www.sec.gov

Material events reported in the last year
- 2026-08-05 reported results of operations and financial condition
- 2026-08-05 made a Regulation FD disclosure · reported another event it considers material
- 2026-07-20 changed its directors or principal officers
- 2026-06-05 reported another event it considers material
- 2026-05-27 changed its directors or principal officers
- 2026-05-20 reported the results of a shareholder vote
- 2026-05-05 reported results of operations and financial condition
- 2026-03-24 changed its directors or principal officers
- 2026-02-26 reported results of operations and financial condition
- 2025-12-16 made a Regulation FD disclosure
- 2025-11-06 reported results of operations and financial condition
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000045/0001964738-26-000045-index.html → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://www.sec.gov
Latest annual report10-K filed 2026-02-27 · for the year ending 2025-12-31
About Solventum Corp, the SEC registrant the site links
Published by a third-party source
Observed via
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/0001964738-26-000007-index.html → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000047/solv-20260630.htm → https://investors.solventum.com/financials/sec-filings/content/0001964738-26-000007/solv-20251231.htm
About
Solventum Corp, the SEC registrant the site links
Read from
https://www.sec.gov

Solventum Employees & Ownership

The latest people collection is incomplete. Previously confirmed people remain available with their original dates.

Abdul DireSolventum lab manager

Stated by 1 source

https://www.solventum.com/en-us/home/our-company/careers/ · Published person (named with a role or their own mailbox on the site) · Solventum lab manager

Published by the company · confirmed Oct 26, 2026, 12:19 AM UTC

First observed: Oct 26, 2026, 12:19 AM UTC

Amy A. WendellAmy A. Wendell, Directorlast seen 2026-05-15

Roles

Former SVP, Strategy and Business Development and Licensing, Covidien · formerhttps://www.solventum.com/en-us/home/our-company/leadership/
Directorhttps://www.sec.gov/Archives/edgar/data/1964738/000140056826000011/wk-form4_1779140149.xml · published 2026-05-15
Tidligere SVP, Strategy and Business Development and Licensing, Covidienhttps://www.solventum.com/da-dk/home/our-company/leadership/
Ehemalige SVP, Strategy and Business Development and Licensing, Covidienhttps://www.solventum.com/de-at/home/our-company/leadership/

As printed Amy A. Wendell was a Senior Advisor for Perella Weinberg Partner’s Healthcare Investment Banking Practice from 2016 to 2019, providing guidance and advice with respect to mergers and acquisitions and divestures for clients and assisting the firm in connection with firm-level transactions. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor for McKinsey’s Strategy and Corporate Finance Practice and also served as a member of McKinsey’s Transactions Advisory Board to help define trends in mergers and acquisitions, as well as help shape McKinsey’s knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including engineering, product management and business development. Most recently, from December 2006 until Covidien’s acquisition by Medtronic plc in January 2015, she served as Senior Vice President of Strategy and Business Development, where she led the company’s strategy and portfolio management initiatives and managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution. Ms. Wendell serves as Lead Director of AxoGen, Inc., where she is a member of the Nominating and Governance Committee and the Audit Committee and at Baxter International, Inc., where she is a member of the Quality, Compliance and Technology Committee and Compensation and Human Capital Committee. She also serves on the board of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science in mechanical engineering from Lawrence Technological University and a Master of Science degree in biomedical engineering from the University of Illinois.
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)
Also named Amy McBride Wendell
Source not recorded

Stated by 7 sources

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Former SVP, Strategy and Business Development and Licensing, Covidien
https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Tidligere SVP, Strategy and Business Development and Licensing, Covidien
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Ehemalige SVP, Strategy and Business Development and Licensing, Covidien
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Former SVP, Strategy and Business Development and Licensing, Covidien
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Former SVP, Strategy and Business Development and Licensing, Covidien
https://www.sec.gov/Archives/edgar/data/1964738/000140056826000011/wk-form4_1779140149.xml · Named as a reporting officer or director in an SEC ownership filing · Director · published 2026-05-15
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Amy A. Wendell, Director · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

Amy LanducciChief Information & Digital Officer

Roles

Chief Information Officerhttps://www.sec.gov/Archives/edgar/data/1964738/000201581326000007/wk-form4_1778875666.xml · published 2026-05-13

As printed Amy Landucci er kendt for at opbygge højtydende teams og har en dokumenteret evne til at gennemføre digitale og teknologiske transformationer inden for sundhedsvæsenet. Som Solventums chief information & digital officer arbejder hun tæt sammen med forretnings- og teknologiledere om at skabe en digital teknologiplatform i verdensklasse, der er nøje afstemt med virksomhedens overordnede forretningsstrategi, og som og gør det muligt for globale aktiviteter at accelerere innovation og vækst. Inden hun kom til Solventum, var amy chief digital & technology officer hos Haleon, hvor hun ledede den tekniske udskillelse fra GSK for at skabe verdens største selvstændige virksomhed inden for personlig sundhedspleje. Før GSK tilbragte hun et årti hos Novartis i en række forskellige roller. De første otte år af sin karriere arbejdede hun som konsulent hos Accenture. Amy har været medlem af bestyrelsen for Healthy Women, den førende uafhængige, non-profit kilde til sundhedsinformation for kvinder i USA.
Published by the company · confirmed Oct 26, 2026, 12:14 AM UTC
Observed via
https://www.solventum.com/da-dk/home/our-company/leadership/ → Published person (name and role labels)

Stated by 5 sources

https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Chief Information & Digital Officer
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Chief Information & Digital Officer
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Chief Information & Digital Officer
https://www.sec.gov/Archives/edgar/data/1964738/000201581326000007/wk-form4_1778875666.xml · Named as a reporting officer or director in an SEC ownership filing · Chief Information Officer · published 2026-05-13
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Chief Information & Digital Officer · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

Balancing riskLessons from a rural health CIO

As printed Dr. Travis Bias, deputy CMO at Solventum, shares actionable takeaways from Phillip Mues, chief information and security officer of Cherry County Hospital, about making high-stakes technology decisions and the lessons he’s learned along the way. Check out the article HealthLeaders
Published by the company · confirmed Oct 26, 2026, 12:15 AM UTC
Observed via
https://www.solventum.com/en-us/home/health-information-technology/news/ → Published person (name and role labels)

Stated by 1 source

https://www.solventum.com/en-us/home/health-information-technology/news/ · Published person (name and role labels) · Lessons from a rural health CIO

Published by the company · confirmed Oct 26, 2026, 12:15 AM UTC

First observed: Oct 26, 2026, 12:15 AM UTC

Bryan HansonChief Executive Officer

Roles

Bryan Hanson, Chief Executive Officer (Principal Executive Officer and Director)https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · published 2026-02-27
Chief Executive Officer, Solventumhttps://www.solventum.com/en-us/home/our-company/leadership/
chief executive officer, Solventumhttps://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors

As printed Bryan Hanson is CEO of Solventum, an $8.2 billion independent healthcare company rooted in a history of diverse expertise spanning the industry — from medical surgical and dental solutions to health information systems. He leads 20,000 problem-solving professionals who work tirelessly every day to enable better, smarter, safer healthcare to improve lives and shape the future of health. Previously known as 3M Health Care, Solventum has a long legacy of creating breakthrough solutions for our customers’ toughest challenges. By pioneering game-changing innovations at the intersection of health, material, and data science, Solventum is advancing solutions that change patient’s lives for the better — while empowering healthcare professionals to perform at their best. Solventum products and services span the healthcare ecosystem, which makes it uniquely positioned to transform patient experiences, improve outcomes and help reduce total cost of care while driving long-term value for shareholders. is a visionary leader who is passionate about transformation and building award-winning organizations. Throughout his 33+ year-career he has successfully led, grown, and transformed global medical device businesses at Zimmer Biomet, Medtronic and Covidien to achieve greater innovation and commercial success and drive value for customers, patients and shareholders. He serves on the board of directors of Walgreens Boots Alliance, Inc.
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)
Also named Bryan C. Hanson · Bryan C Hanson
Source not recorded

Stated by 14 sources (11 listed)

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Chief Executive Officer
https://www.solventum.com/de-at/home/our-company/ · Published person (named with a role in the page's text) · Chief Executive Officer
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Chief Executive Officer, Solventum
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Chief Executive Officer
https://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors · Published person (name and role labels) · chief executive officer, Solventum
https://www.solventum.com/da-dk/home/our-company/ · Published person (name and role labels) · Chief Executive Officer
https://www.solventum.com/da-dk/home/our-company/careers/ · Published person (name and role labels) · Chief Executive Officer
https://www.solventum.com/en-us/home/our-company/ · Published person (name and role labels) · Chief Executive Officer
https://www.solventum.com/en-us/home/our-company/partners-suppliers/supplier-engagement/ · Published person (name and role labels) · Chief Executive Officer
https://www.sec.gov/Archives/edgar/data/1964738/000152434926000008/wk-form4_1788466256.xml · Named as a reporting officer or director in an SEC ownership filing · Chief Executive Officer · published 2026-09-01
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000017/R2.htm · Named in a capacity in the registrant's SEC filing · published 2026-03-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:13 AM UTC

Carlos AlbánCarlos Albán, Directorlast seen 2026-05-15

Roles

Ehemaliger Vice Chairman und Chief Commercial Officer, AbbVie, Inc.https://www.solventum.com/de-at/home/our-company/leadership/
Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc. · formerhttps://www.solventum.com/en-us/home/our-company/leadership/
former vice chairman and chief commercial officer, AbbVie, Inc. · formerhttps://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors
Tidligere vice chairman og chief commercial officer, AbbVie, Inc.https://www.solventum.com/da-dk/home/our-company/leadership/
Chairhttps://investors.solventum.com/governance/board-committees
Directorhttps://www.sec.gov/Archives/edgar/data/1964738/000147463226000008/wk-form4_1779140395.xml · published 2026-05-15

As printed Carlos Albán is a seasoned pharmaceutical executive with more than 30 years of experience in global commercial strategy and operations. From December 2018 until March 2021, Mr. Albán served as Vice Chairman, Chief Commercial Officer of AbbVie, Inc., responsible for global commercial operations, including the Pharmacyclics commercial functions. From January 2013 until December 2018, he served as AbbVie’s Executive Vice President, Commercial Operations. From February 2011 until December 2012, Mr. Albán served as Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations for Abbott Laboratories, Inc., and previously served at Abbott as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Pharmaceuticals, Western Europe and Canada Operations from 2007 to 2009, as Vice President, Pharmaceuticals, European Operations from 2006 to 2007, as Regional Director for the Northern Europe area of the international pharmaceutical business from 2004 to 2006, and General Manager, Portugal from 2002 to 2004. Mr. Albán currently serves on the board of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. Mr. Albán received a degree in economics from Pontificia Universidad Javeriana in Bogotá, Colombia.
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)
Also named Carlos Alban
Source not recorded

Stated by 9 sources

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc.
https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Tidligere vice chairman og chief commercial officer, AbbVie, Inc.
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Ehemaliger Vice Chairman und Chief Commercial Officer, AbbVie, Inc.
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc.
https://investors.solventum.com/governance/board-committees · Published person (named with a role or their own mailbox on the site) · Chair
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Former Vice Chairman and Chief Commercial Officer, AbbVie, Inc.
https://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors · Published person (name and role labels) · former vice chairman and chief commercial officer, AbbVie, Inc.
https://www.sec.gov/Archives/edgar/data/1964738/000147463226000008/wk-form4_1779140395.xml · Named as a reporting officer or director in an SEC ownership filing · Director · published 2026-05-15
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Carlos Albán, Director · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

Carrie S. CoxCarrie S. Cox, Chair of the Board of Directors

Roles

former chief executive officer, Humacyte, Inc. · formerhttps://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors
Tidligere chief executive officer, Humacyte, Inc.https://www.solventum.com/da-dk/home/our-company/leadership/
Chair of the Board; Former Chief Executive Officer, Humacyte, Inc.https://investors.solventum.com/governance/board-of-directors
Ehemalige Chief Executive Officer, Humacyte, Inc.https://www.solventum.com/de-at/home/our-company/leadership/
Chairhttps://investors.solventum.com/governance/board-committees
Former Chief Executive Officer, Humacyte, Inc. · formerhttps://www.solventum.com/en-us/home/our-company/leadership/
Directorhttps://www.sec.gov/Archives/edgar/data/1964738/000111075326000006/wk-form4_1779140353.xml · published 2026-05-15

As printed Carrie S. Cox most recently served as the Chief Executive Officer of Humacyte, Inc., a then privately-held regenerative medicine company, between 2010 and 2018; in addition, she served as Chairman of the company’s board between 2013 and 2019, and she remained a member of its board until 2021, prior to its public offering. Ms. Cox served as Executive Vice President of Schering-Plough Corporation and President of Schering-Plough’s global pharmaceutical business between 2003 and 2009, when Schering-Plough merged with Merck. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s global pharmaceutical business from 1997 until its merger with Pfizer Inc. in 2003. She currently serves as Chairman of Organon & Co. and Cartesian Therapeutics, Inc. and as a director of Texas Instruments Inc. She served on the Board of Directors of Cardinal Health Inc. from 2009 to 2023, on the Board of Directors of Celgene Corporation from 2009 until its acquisition by Bristol-Myers Squibb Company in 2019, as Chairman of the Board of Directors of electroCore, Inc. between 2018 and 2020, and as Chairman of the Board of Directors of Array BioPharma Inc. from 2018 until its acquisition by Pfizer Inc. in 2019. Ms. Cox is a graduate of the Massachusetts College of Pharmacy and has been named six times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business.”
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)
Also named Carrie Smith Cox
Source not recorded

Stated by 9 sources

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Chair of the Board; Former Chief Executive Officer, Humacyte, Inc.
https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Tidligere chief executive officer, Humacyte, Inc.
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Ehemalige Chief Executive Officer, Humacyte, Inc.
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Former Chief Executive Officer, Humacyte, Inc.
https://investors.solventum.com/governance/board-committees · Published person (named with a role or their own mailbox on the site) · Chair
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Chair of the Board; Former Chief Executive Officer, Humacyte, Inc.
https://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors · Published person (name and role labels) · former chief executive officer, Humacyte, Inc.
https://www.sec.gov/Archives/edgar/data/1964738/000111075326000006/wk-form4_1779140353.xml · Named as a reporting officer or director in an SEC ownership filing · Director · published 2026-05-15
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Carrie S. Cox, Chair of the Board of Directors · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

C.R. BardPresident and COOformer

Roles

President and COO · formerhttps://investors.solventum.com/governance/board-of-directors

Stated by 1 source

https://investors.solventum.com/governance/board-of-directors · Published person (named with a role or their own mailbox on the site) · President and COO

Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC

First observed: Oct 26, 2026, 12:16 AM UTC

Custom digitalHours of operations

Emailorthosupport@solventum.comOrthodontic · in the page's links or structured data
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://www.solventum.com/en-us/home/oral-care/support/
Emailcustomortho@solventum.comCustom digital · in the page's links or structured data
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://www.solventum.com/en-us/home/oral-care/support/
Phone1-800-423-4588
Published by the company
Observed via
https://www.solventum.com/en-us/home/oral-care/support/ → A route the site prints with the person (joined on evidence)

Stated by 1 source

https://www.solventum.com/en-us/home/oral-care/support/ · Published person (page markup) · Hours of operations

Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC

First observed: Oct 26, 2026, 12:16 AM UTC

Dan BassSolventum clinical terminologist

Stated by 1 source

https://www.solventum.com/en-us/home/our-company/careers/ · Published person (named with a role or their own mailbox on the site) · Solventum clinical terminologist

Published by the company · confirmed Oct 26, 2026, 12:19 AM UTC

First observed: Oct 26, 2026, 12:19 AM UTC

Darryl L. WilsonDarryl L. Wilson, Directorlast seen 2026-05-15

Roles

former vice president, commercial, GE · formerhttps://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors
Directorhttps://www.sec.gov/Archives/edgar/data/1964738/000175550826000008/wk-form4_1779140123.xml · published 2026-05-15
Former Vice President, Commercial, GE Power, General Electric Company · formerhttps://www.solventum.com/en-us/home/our-company/leadership/
Tidligere Vice President, Commercial, GE Power hos General Electric Companyhttps://www.solventum.com/da-dk/home/our-company/leadership/
Ehemaliger Vice President, Commercial, GE Power, General Electric Companyhttps://www.solventum.com/de-at/home/our-company/leadership/

As printed Darryl Wilson is a strategic business executive who has built highly successful organizations and led complex business transformations at General Electric and British Petroleum businesses around the world for more than 35 years. Darryl was a Vice President and Corporate Officer of the General Electric Company. After leaving GE in 2017, Darryl founded The Wilson Collective, an investment and business advisory firm that advises, consults and invests in a portfolio of businesses. He serves on the NextEra Energy Board of Directors, Audit and Compensation Committees and also serves on the Eaton Corporation Board of Directors, Audit and Governance Committees. He also serves on the Primerica Board of Directors. He served as Chairman of the Board of the Dallas Federal Reserve - Houston Branch; Houston Endowment - Finance and Investment Committees; Texas Children's Hospital - Finance and Public Policy Committees; The Kinkaid School Board of Trustees - Finance and Endowment Committees. Darryl also served on the Dallas Federal Reserve Board, Energy Advisory Committee. Darryl held P&L leader roles based internationally in Canada; Budapest, Hungary; London, England and Shanghai, China. He held CEO roles in Asia Pacific, Europe, Middle East and Africa for GE Consumer and Industrial. He served as President & CEO of GE Aero Derivatives Energy, a global aircraft engine technology business and also served as President & CEO GE Consumer Products EMEA. In his final GE position, Darryl was Vice President, Commercial in the GE Power division, leading global sales and marketing for a $38B provider of power generation, transmission, distribution and services. Darryl joined GE in 1992, after earning an MBA in Marketing from Indiana University. He has a BA in Business Administration from Baldwin Wallace College in Ohio and spent the first six years of his career in the Executive Development Program at British Petroleum North America in Cleveland, Ohio. He has been active in many other community organizations; Darryl is a former Board Member and Executive Committee Member of the Greater Houston Partnership, The Houston Food Bank, The American Heart Association, The Dream Foundation, The East End Neighborhood Center and The Greater Cleveland Urban League. Darryl also served on several corporate boards representing General Electric affiliates, and joint ventures internationally. He was appointed by GE and the US Government to the US and Mexico Energy council.
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)

Stated by 8 sources

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Former Vice President, Commercial, GE Power, General Electric Company
https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Tidligere Vice President, Commercial, GE Power hos General Electric Company
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Ehemaliger Vice President, Commercial, GE Power, General Electric Company
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Former Vice President, Commercial, GE Power, General Electric Company
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Former Vice President, Commercial, GE Power, General Electric Company
https://investors.solventum.com/news-events/press-releases/detail/118/solventum-names-shirley-edwards-to-board-of-directors · Published person (name and role labels) · former vice president, commercial, GE
https://www.sec.gov/Archives/edgar/data/1964738/000175550826000008/wk-form4_1779140123.xml · Named as a reporting officer or director in an SEC ownership filing · Director · published 2026-05-15
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Darryl L. Wilson, Director · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

Dr. Bernard A. Harris Jr.Dr. Bernard A. Harris Jr., Directorlast seen 2026-05-15

Roles

Chief Executive Officer und Managing Partner, Versalius Ventures, Inc.https://www.solventum.com/de-at/home/our-company/leadership/
Chief Executive Officer og Managing Partner, Versalius Ventures, Inc.https://www.solventum.com/da-dk/home/our-company/leadership/
Directorhttps://www.sec.gov/Archives/edgar/data/1964738/000133790626000006/wk-form4_1779140251.xml · published 2026-05-15
Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.https://investors.solventum.com/governance/board-of-directors

As printed Dr. Bernard A. Harris Jr., is chief executive officer and managing partner of Vesalius Ventures, Inc. He served as a trustee/director for Salient and Barings investment funds. He currently serves on the boards of Raytheon Technologies (NYSE: RTX), U.S. Physical Therapy (NYSE: USPH) and MassMutual. He also served as a board member for the National Academies of Science, Engineering and Medicine - Board on Health Sciences Policy, and is currently on the boards of the Texas Medical Center and the Harris Foundation, which he founded. Dr. Harris is a former NASA astronaut, has logged more than 438 hours and traveled over 7.2 million miles in space. He was a mission specialist on the space shuttle Columbia in 1993 and a payload commander on space shuttle Discovery in 1995, where he became the first African American to walk in space. He earned a Bachelor of Science in Biology from the University of Houston, a Master of Medical Science from the University of Texas Medical Branch at Galveston, a Master of Business Administration from the University of Houston – Clear Lake, and a Doctor of Medicine from Texas Tech University Health Sciences Center School of Medicine. He completed a residency in internal medicine at the Mayo Clinic, a National Research Council Fellowship in endocrinology at the NASA Ames Research Center and trained as a flight surgeon at the United States Air Force School of Aerospace Medicine. He is a fellow of the American College of Physicians, and a member of the American Academy of Arts and Sciences.
Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC
Observed via
https://investors.solventum.com/governance/board-of-directors → Published person (name and role labels)
Also named Bernard A Harris Jr
Source not recorded

Stated by 7 sources

https://investors.solventum.com/governance/board-of-directors · Published person (name and role labels) · Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.
https://www.solventum.com/da-dk/home/our-company/leadership/ · Published person (name and role labels) · Chief Executive Officer og Managing Partner, Versalius Ventures, Inc.
https://www.solventum.com/de-at/home/our-company/leadership/ · Published person (name and role labels) · Chief Executive Officer und Managing Partner, Versalius Ventures, Inc.
https://www.solventum.com/en-us/home/our-company/leadership/ · Published person (name and role labels) · Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.
https://investors.solventum.com/governance/board-of-directors · Published person (schema.org) · Chief Executive Officer and Managing Partner, Versalius Ventures, Inc.
https://www.sec.gov/Archives/edgar/data/1964738/000133790626000006/wk-form4_1779140251.xml · Named as a reporting officer or director in an SEC ownership filing · Director · published 2026-05-15
https://www.sec.gov/Archives/edgar/data/1964738/000196473826000007/solv-20251231.htm · Named in a capacity in the registrant's SEC filing · Dr. Bernard A. Harris Jr., Director · published 2026-02-27

Published by the company · confirmed Oct 26, 2026, 12:20 AM UTC

First observed: Oct 26, 2026, 12:14 AM UTC

Job Postings

441 job listings.

(Sr.) Account Manager,Lava,Dental CN, Shanghai · ID R01130919
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
(Sr.) Account Manager,Lava,Dental
Identifier
R01130919
Recruiting platform
workday
Published location
CN, Shanghai
3rd Shift Production Specialist US, Missouri, Columbia · ID R01132280
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
3rd Shift Production Specialist
Identifier
R01132280
Recruiting platform
workday
Published location
US, Missouri, Columbia
AI Architect - Modern AI Applications IN, BANGALORE · ID R01132964
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI Architect - Modern AI Applications
Identifier
R01132964
Recruiting platform
workday
Published location
IN, BANGALORE
AI Cloud Engineer IN, Bangalore Kar · ID R01132692-1
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI Cloud Engineer
Identifier
R01132692-1
Recruiting platform
workday
Published location
IN, Bangalore Kar
AI Product Owner Remote - Utah · ID R01131306
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI Product Owner
Identifier
R01131306
Recruiting platform
workday
Published location
Remote - Utah
AI/ML Engineer IN, Bangalore Kar · ID R01131749-1
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI/ML Engineer
Identifier
R01131749-1
Recruiting platform
workday
Published location
IN, Bangalore Kar

AI/ML Engineer IN, Bangalore Kar · ID R01134418
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI/ML Engineer
Identifier
R01134418
Recruiting platform
workday
Published location
IN, Bangalore Kar
AI/ML Engineer IN, Bangalore Kar · ID R01134422
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI/ML Engineer
Identifier
R01134422
Recruiting platform
workday
Published location
IN, Bangalore Kar
AI/ML Technical Manager MX, Mexico City, Virtual · ID R01134098
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
AI/ML Technical Manager
Identifier
R01134098
Recruiting platform
workday
Published location
MX, Mexico City, Virtual
ANZ Product Marketing Manager - Indirect Restoratives AU, New South Wales, North Ryde · ID R01133739
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
ANZ Product Marketing Manager - Indirect Restoratives
Identifier
R01133739
Recruiting platform
workday
Published location
AU, New South Wales, North Ryde
ANZ Special Markets Manager – Solventum Dental Solutions AU, New South Wales, North Ryde · ID R01130988
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
ANZ Special Markets Manager – Solventum Dental Solutions
Identifier
R01130988
Recruiting platform
workday
Published location
AU, New South Wales, North Ryde
APAC Marketing Development Manager,Dental,SG SG, Singapore · ID R01127512
Recruiting platform
workday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
All published fields
Title
APAC Marketing Development Manager,Dental,SG
Identifier
R01127512
Recruiting platform
workday
Published location
SG, Singapore

Hiring evidence

Recruiting platformworkday
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
Boardhealthcare.wd1/Search
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
Open roles431
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://healthcare.wd1.myworkdayjobs.com/wday/cxs/healthcare/Search/jobs
Read from
https://healthcare.wd1.myworkdayjobs.com
Recruiting platformpublisher_listed
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://www.solventum.com/en-us/home/our-company/careers/
Read from
https://www.solventum.com
Board
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://www.solventum.com/en-us/home/our-company/careers/
Read from
https://www.solventum.com
Open roles10
Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC
Observed via
publisher careers link → resolved board identity → https://www.solventum.com/en-us/home/our-company/careers/
Read from
https://www.solventum.com

Contact Information

Emails

solventumhismktg@solventum.com (Thank you for reaching out)
; oralcareproducts@solventum.com (Dental)
; hrhelpamericas@solventum.com
; news@solventum.com (Pressekontakt)
; Privacy@solventum.com (Your rights regarding protected health information about you)
; jpmcgough@solventum.com (Email Address)
; supplierdiversityusa@solventum.com (Email us to request tier 2 report)
; supplieronboarding@solventum.com (rer)

solventumhismktg@solventum.com

A member of our team will be in touch to schedule time to connect. If you have any questions, please contact solventumhismktg@solventum.com .

Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/en-us/home/health-information-technology/resources-education/events/
First observed: Oct 26, 2026, 12:16 AM UTC

oralcareproducts@solventum.com

Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/en-us/home/oral-care/support/
First observed: Oct 26, 2026, 12:16 AM UTC

hrhelpamericas@solventum.com

If you need special assistance or an accommodation for a disability in order to apply for a posted position, contact our Human Resources department at hrhelpamericas@solventum.com or by phone at 1 (61

Published by the company · confirmed Oct 26, 2026, 12:15 AM UTC

Observed via: https://www.solventum.com/en-us/home/our-company/careers/
First observed: Oct 26, 2026, 12:15 AM UTC

news@solventum.com

Pressekontakt : news@solventum.com

Published by the company · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/da-dk/home/our-company/contact-us/ → role address by local-part convention (RFC 2142)
First observed: Oct 26, 2026, 12:16 AM UTC

Privacy@solventum.com

Right to a Paper Copy of This Notice . You have the right to a paper copy of this Notice. You may ask us to give you a copy of this Notice at any time. Even if you have agreed to receive this Notice e

Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC

Observed via: https://www.solventum.com/en-us/home/our-company/hipaa-privacy/ → role address by local-part convention
First observed: Oct 26, 2026, 12:13 AM UTC

jpmcgough@solventum.com

Email Address: jpmcgough@solventum.com

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/en-us/home/our-company/leadership/governance/ → printed in page text, not marked up
First observed: Oct 26, 2026, 12:16 AM UTC

supplierdiversityusa@solventum.com

Published by the company · confirmed Oct 26, 2026, 12:17 AM UTC

Observed via: https://www.solventum.com/en-us/home/our-company/partners-suppliers/supplier-engagement/
First observed: Oct 26, 2026, 12:17 AM UTC

supplieronboarding@solventum.com

Partnere og leverandører: supplieronboarding@solventum.com

Published by the company · confirmed Oct 26, 2026, 12:14 AM UTC

Observed via: https://www.solventum.com/da-dk/home/our-company/contact-us/
First observed: Oct 26, 2026, 12:14 AM UTC

Phones

+1-855-423-6725 (customer service)
; 1-800-634-2249 (Dental)
; 252.227-7013 (Brugere blandt de amerikanske myndigheder)

+1-855-423-6725

1-855-423-6725 (1-855-HC FOR ALL)

Published by the company · confirmed Oct 26, 2026, 12:14 AM UTC

Observed via: https://www.solventum.com/en-us/home/
First observed: Oct 26, 2026, 12:14 AM UTC

1-800-634-2249

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/en-us/home/oral-care/support/ → printed in page text, not marked up
First observed: Oct 26, 2026, 12:16 AM UTC

252.227-7013

Brug, duplikering eller videregivelse af den amerikanske regering er underlagt de begrænsninger, der er fremsat i DFARS 252.227-7013(c)(1)(ii) og FAR 52.227-19 og eventuelle andre efterfølgende bestem

Directly observed · confirmed Oct 26, 2026, 12:14 AM UTC

Observed via: https://www.solventum.com/da-dk/home/legal/ → printed in page text, not marked up
First observed: Oct 26, 2026, 12:14 AM UTC

External references

Emails

notification@payference.com

notification@payference.com

To ensure delivery of emails from Serrala, please add notification@payference.com to your allowed senders list or whitelist this email address.

Directly observed · confirmed Oct 26, 2026, 12:15 AM UTC

Observed via: https://www.solventum.com/en-us/home/health-information-technology/support/ → printed in page text, not marked up → address on another registrable domain — referenced, not the subject's contact point → printed beside it: "To ensure delivery of emails from Serrala, please add notification@payference.com to your allowed senders list or whitelist this email address."
First observed: Oct 26, 2026, 12:15 AM UTC

More contact information (30)

Contact forms

https://www.solventum.com/da-dk/home/medical/surgical-solutions/

Directly observed · confirmed Oct 26, 2026, 12:14 AM UTC

Observed via: https://www.solventum.com/da-dk/home/medical/surgical-solutions/ → form headed "Kontakt en Solventum-repræsentant" → submits to https://www.solventum.com/da-dk/home/medical/surgical-solutions/ → purpose: support (an order-number field or a subject select, and a way to reply) → https://www.solventum.com/da-dk/home/medical/sterilization-assurance/
First observed: Oct 26, 2026, 12:14 AM UTC

https://www.solventum.com/da-dk/home/our-company/partners-suppliers/

Directly observed · confirmed Oct 26, 2026, 12:20 AM UTC

Observed via: https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → form headed "SAP Business Network (Ariba)" → submits to https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → purpose: contact (a way to reply and a free-text field)
First observed: Oct 26, 2026, 12:20 AM UTC

https://www.solventum.com/da-dk/home/our-company/partners-suppliers/

Directly observed · confirmed Oct 26, 2026, 12:18 AM UTC

Observed via: https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → form headed "Samarbejde i forsyningskæden" → submits to https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → purpose: contact (a way to reply and a free-text field)
First observed: Oct 26, 2026, 12:18 AM UTC

https://www.solventum.com/de-at/home/medical/surgical-solutions/temperature-management/

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/de-at/home/medical/surgical-solutions/temperature-management/ → form headed "Kontaktieren Sie einen Solventum-Ansprechpartner" → submits to https://www.solventum.com/de-at/home/medical/surgical-solutions/temperature-management/ → purpose: support (an order-number field or a subject select, and a way to reply)
First observed: Oct 26, 2026, 12:16 AM UTC

https://www.solventum.com/en-us/home/f/b5005365001/

Directly observed · confirmed Oct 26, 2026, 12:19 AM UTC

Observed via: https://www.solventum.com/en-us/home/f/b5005365001/ → form headed "Contact a Solventum representative" → submits to https://www.solventum.com/en-us/home/f/b5005365001/ → purpose: contact (a way to reply and a free-text field)
First observed: Oct 26, 2026, 12:19 AM UTC

https://www.solventum.com/da-dk/home/medical/iv-site-management/

Directly observed · confirmed Oct 26, 2026, 12:13 AM UTC

Observed via: https://www.solventum.com/da-dk/home/medical/iv-site-management/ → form headed "Kontakt en Solventum-repræsentant" → submits to https://www.solventum.com/da-dk/home/medical/iv-site-management/ → purpose: support (an order-number field or a subject select, and a way to reply) → https://www.solventum.com/da-dk/home/medical/advanced-wound-care/
First observed: Oct 26, 2026, 12:13 AM UTC

https://www.solventum.com/da-dk/home/medical/iv-site-management/disinfecting-port-protectors/

Directly observed · confirmed Oct 26, 2026, 12:15 AM UTC

Observed via: https://www.solventum.com/da-dk/home/medical/iv-site-management/disinfecting-port-protectors/ → form headed "Kontakt en Solventum-repræsentant" → submits to https://www.solventum.com/da-dk/home/medical/iv-site-management/disinfecting-port-protectors/ → purpose: support (an order-number field or a subject select, and a way to reply) → https://www.solventum.com/da-dk/home/medical/iv-site-management/iv-dressings/ → https://www.solventum.com/da-dk/home/medical/iv-site-management/iv-training/ → https://www.solventum.com/da-dk/home/medical/patient-monitoring-and-management/ → https://www.solventum.com/da-dk/home/medical/patient-monitoring-and-management/ecg-electrodes/ → https://www.solventum.com/da-dk/home/medical/patient-monitoring-and-management/medical-tapes-wraps-and-securement-devices/ → https://www.solventum.com/da-dk/home/medical/patient-monitoring-and-management/pharmacy-solutions/
First observed: Oct 26, 2026, 12:15 AM UTC

https://www.solventum.com/da-dk/home/medical/surgical-solutions/temperature-management/

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/da-dk/home/medical/surgical-solutions/temperature-management/ → form headed "Kontakt en Solventum-repræsentant" → submits to https://www.solventum.com/da-dk/home/medical/surgical-solutions/temperature-management/ → purpose: support (an order-number field or a subject select, and a way to reply)
First observed: Oct 26, 2026, 12:16 AM UTC

https://www.solventum.com/da-dk/home/our-company/partners-suppliers/

Directly observed · confirmed Oct 26, 2026, 12:18 AM UTC

Observed via: https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → form headed "BTP Case Management Tool" → submits to https://www.solventum.com/da-dk/home/our-company/partners-suppliers/ → purpose: contact (a way to reply and a free-text field)
First observed: Oct 26, 2026, 12:18 AM UTC

https://www.solventum.com/en-us/home/purification-filtration/manufacturing/food-beverage/

Directly observed · confirmed Oct 26, 2026, 12:14 AM UTC

Observed via: https://www.solventum.com/en-us/home/purification-filtration/manufacturing/food-beverage/ → form headed "Ask an expert" → submits to https://www.solventum.com/en-us/home/purification-filtration/manufacturing/food-beverage/ → purpose: contact (a way to reply and a free-text field)
First observed: Oct 26, 2026, 12:14 AM UTC

https://www.solventum.com/en-us/home/medical/surgical-solutions/temperature-management/

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/en-us/home/medical/surgical-solutions/temperature-management/ → form headed "Contact a Solventum representative" → submits to https://www.solventum.com/en-us/home/medical/surgical-solutions/temperature-management/ → purpose: contact (its heading names it)
First observed: Oct 26, 2026, 12:16 AM UTC

https://www.solventum.com/de-at/home/medical/iv-site-management/disinfecting-port-protectors/

Directly observed · confirmed Oct 26, 2026, 12:16 AM UTC

Observed via: https://www.solventum.com/de-at/home/medical/iv-site-management/disinfecting-port-protectors/ → form headed "Kontaktieren Sie einen Solventum-Ansprechpartner" → submits to https://www.solventum.com/de-at/home/medical/iv-site-management/disinfecting-port-protectors/ → purpose: support (an order-number field or a subject select, and a way to reply) → https://www.solventum.com/de-at/home/medical/iv-site-management/iv-dressings/ → https://www.solventum.com/de-at/home/medical/iv-site-management/iv-training/ → https://www.solventum.com/de-at/home/medical/patient-monitoring-and-management/ → https://www.solventum.com/de-at/home/medical/patient-monitoring-and-management/ecg-electrodes/ → https://www.solventum.com/de-at/home/medical/patient-monitoring-and-management/medical-tapes-wraps-and-securement-devices/ → https://www.solventum.com/de-at/home/medical/patient-monitoring-and-management/pharmacy-solutions/ → https://www.solventum.com/de-at/home/medical/treatments-conditions-specialties/exudate-management/
First observed: Oct 26, 2026, 12:16 AM UTC

Full contact-form data (JSON)

Locations evidence

Locations

View evidence

Location data

The latest location collection is incomplete.

No confirmed restaurant locations are currently attached to this site.

Menus evidence

Menu & Online Ordering

Menu & price evidence

View brochure
4 items · from https://www.solventum.com/content/dam/public/language-masters/en/pfb/document/2012/Beer-Filtration-Cat.pdf
Smarter brewing starts here
Contents
- Water filtration solutions6
- Trap filtration solutions7
- D.E. trap, water & beer clarification8
- Application engineering expertise14
  Gas control solutions... 12–13
Craft with confidence
Performance
Ease of use
Quality
Brewing process
Pre-filter
Final filter
Bottling
Water pretreatment solutions:
Final filtration solutions:
Prefilter haze control solutions:
D.E. trap filtration solutions:
Quality beer comes from quality water
3M™ Micro-Klean™ RT Series Filters
Rigid depth filter construction
Larger volume requirements or space restrictions?
Other applications
Bottle and keg washing water
Sanitizing water
Help protect your downstream process
3M™ Betafine™ XL Series Filters
How it works
Why it matters
3M™ Betapure™ NT Series Filters
Get high flow capacity in a compact design
3M™ High Flow Series Filter System
Compact design
Absolute rating
Polypropylene construction
Easy to use
Solutions for small brewers
For smaller brewers, we recommend:
Are filter presses slowing you down?
3M™ Zeta Plus™ H Series Filters
3M™ Zeta Plus™ Dual-Zone MH Series Filters
Want more haze in your beer?
Advantages of lenticular filters vs. filter presses
Published by the company · confirmed Oct 26, 2026, 12:15 AM UTC
Observed via
https://www.solventum.com/content/dam/public/language-masters/en/pfb/document/2012/Beer-Filtration-Cat.pdf
First observed
Oct 26, 2026, 12:15 AM UTC
Read from
https://www.solventum.com
Menu document read in part10 of 16 pages of https://www.solventum.com/content/dam/public/language-masters/en/pfb/document/2012/Beer-Filtration-Cat.pdf
Derived from observations · confirmed Oct 26, 2026, 12:15 AM UTC
Observed via
https://www.solventum.com/content/dam/public/language-masters/en/pfb/document/2012/Beer-Filtration-Cat.pdf
First observed
Oct 26, 2026, 12:15 AM UTC
Read from
https://www.solventum.com

Channel pricing evidence

Channel pricing

View evidence

Nothing observed in this category.

Website & Digital Technology

solventum.com was first registered on February 11, 2007. Its registrar is CSC Corporate Domains, Inc..

Protocols: TLS 1.3 and HTTP/2.

HTTPS certificate: Sectigo Limited, expires January 22, 2027.

DNSSEC was not enabled when observed.

View technology, DNS, network and security evidence

More website details

View mail records and evidence

Apps, Loyalty & Guest Technology

View apps, provider accounts and technical evidence

App store details: Nothing observed in this category.

Publisher files

Web app manifesthttps://www.solventum.com/etc.clientlibs/healthcareweb/clientlibs/clientlib-site/resources/site.webmanifest
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → https://www.solventum.com/etc.clientlibs/healthcareweb/clientlibs/clientlib-site/resources/site.webmanifest
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
App display modestandalone
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → https://www.solventum.com/etc.clientlibs/healthcareweb/clientlibs/clientlib-site/resources/site.webmanifest
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
App theme colour#ffffff
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → https://www.solventum.com/etc.clientlibs/healthcareweb/clientlibs/clientlib-site/resources/site.webmanifest
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com
App icons declared2
Published by the company · confirmed Oct 26, 2026, 12:13 AM UTC
Observed via
https://www.solventum.com/en-us/home/ → https://www.solventum.com/etc.clientlibs/healthcareweb/clientlibs/clientlib-site/resources/site.webmanifest
First observed
Oct 26, 2026, 12:13 AM UTC
Read from
https://www.solventum.com

Feeds

Nothing observed in this category.

GitHub

Nothing observed in this category.

Additional site intelligence

Useful site-graph evidence is available on demand instead of being pre-rendered into every company profile.

12 Months Ended	2025-12-31	2024-12-31	2023-12-31
Cost of product	6,349,000,000	6,348,000,000	6,296,000,000
Cost of software and rentals	1,976,000,000	1,906,000,000	1,901,000,000

Solventum

Legal Entities & Relationships

What other sites’ records say

SEC EDGAR

Solventum Employees & Ownership

Job Postings

Contact Information

Locations evidence

Locations

Menus evidence

Menu & Online Ordering

Channel pricing evidence

Channel pricing

Website & Digital Technology

Who manages Solventum's domain and DNS?

What web infrastructure does Solventum use?

How is Solventum's website secured?

Does Solventum use DNSSEC?

More website details

Apps, Loyalty & Guest Technology

Publisher files

Feeds

GitHub

Additional site intelligence